熱門資訊> 正文
Janux Therapeutics GAAP每股收益为-0.30美元，击败0.03美元
2024-05-08 05:59
- Janux Therapeutics press release (NASDAQ:JANX): Q1 GAAP EPS of -$0.30 beats by $0.03.
- As of March 31, 2024, Janux reported cash and cash equivalents and short-term investments of $651.8 million compared to $344.0 million at December 31, 2023.
- Shares -1.63% AH.
More on Janux Therapeutics
- Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
- Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
- Trial Data Triggers Massive Rally In Janux Therapeutics
- Janux Therapeutics gains amid renewed takeover speculation
- Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
